Synergistic antitumor responses by combined GITR activation and sunitinib in metastatic renal cell carcinoma

International Journal of Cancer

Volumn 138, Issue 2, 2016, Pages 451-462

  Yu, Nengwang ^a   Fu, Shuai ^b   Xu, Zhonghua ^c   Liu, Yi ^a   Hao, Junwen ^a   Zhang, Aimin ^a   Wang, Baocheng ^a  

^a JINAN MILITARY GENERAL HOSPITAL   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

anti GITR; immunotherapy; metastatic renal cancer; Sunitinib

Indexed keywords

ANTINEOPLASTIC AGENT; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; PYRROLE DERIVATIVE; SUNITINIB;

AGONISTS; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CD8+ T LYMPHOCYTE; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY CARCINOMA; KIDNEY TUMOR; LYMPHOCYTE ACTIVATION; MACROPHAGE; MACROPHAGE ACTIVATION; MOUSE; NATURAL KILLER CELL; PATHOLOGY; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FEMALE; GLUCOCORTICOID-INDUCED TNFR-RELATED PROTEIN; IMMUNOTHERAPY; INDOLES; KIDNEY NEOPLASMS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PYRROLES;

EID: 84955687298     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29713     Document Type: Article

References (50)

1. Gupta K, Miller JD, Li JZ, et al., Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treatment Rev 2008; 34: 193-205.
2. Scherr AJ, Lima JP, Sasse EC, et al., Adjuvant therapy for locally advanced renal cell cancer: a systematic review with meta-analysis. BMC Cancer 2011; 11: 115.
3. Klapper JA, Downey SG, Smith FO, et al., High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 2008; 113: 293-301.
4. Singer EA, Gupta GN, Srinivasan R., Targeted therapeutic strategies for the management of renal cell carcinoma. Curr Opin Oncol 2012; 24: 284-90.
5. Pal SK, Williams S, Josephson DY, et al., Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm. Mol Cancer Therap 2012; 11: 526-37.
6. Escudier B., Emerging immunotherapies for renal cell carcinoma. Ann Oncol 2012; 23: viii35-40.
7. Kopecky O, Lukesova S, Vroblova V, et al., Phenotype analysis of tumour-infiltrating lymphocytes and lymphocytes in peripheral blood in patients with renal carcinoma. Acta Med (Hradec Kralove) 2007; 50: 207-12.
8. Bhatia S, Curti B, Ernstoff MS, et al., Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. J Immunotherapy Cancer 2014; 2: 2.
9. Rini BI, Stein M, Shannon P, et al., Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 2011; 117: 758-67.
10. McDermott DF, Drake CG, Sznol M, et al., A phase I study to evaluate safety and antitumor activity of biweekly BMS-936558 (Anti-PD-1, MDX-1106/ONO-4538) in patients with RCC and other advanced refractory malignancies. J Clin Oncol 2011; 29:(suppl 7; abstr 331).
11. Figlin RA, Nicolette CA, Amin A, et al., Monitoring T-cell responses in a phase II study of AGS-003, an autologous dendritic cell-based therapy in patients with newly diagnosed advanced stage renal cell carcinoma in combination with sunitinib. J Clin Oncol 2011; 29:(suppl; abstr 2532).
12. Ozao-Choy J, Ma G, Kao J, et al., The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009; 69: 2514-22.
13. Finke JH, Rini B, Ireland J, et al., Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008; 14: 6674-82.
14. Ko JS, Zea AH, Rini BI, et al., Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15: 2148-57.
15. Motz GT, Coukos G., Deciphering and reversing tumor immune suppression. Immunity 2013; 39: 61-73.
16. Jaini R, Rayman P, Cohen PA, et al., Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy. Int J Cancer J Int Du Cancer 2014; 134: 1695-705.
17. Bose A, Taylor JL, Alber S, et al., Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer J Int Du Cancer 2011; 129: 2158-70.
18. Vanneman M, Dranoff G., Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012; 12: 237-51.
19. Yao S, Zhu Y, Chen L., Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discover 2013; 12: 130-46.
20. Melero I, Grimaldi AM, Perez-Gracia JL, et al., Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res 2013; 19: 997-1008.
21. Pal SK, Hu A, Chang M, et al., Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions. Clin Adv Hematol Oncol 2014; 12: 90-9.
22. Massari F, Santoni M, Ciccarese C, et al., PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises. Cancer Treatment Rev 2015; 41: 114-21.
23. Melero I, Hirschhorn-Cymerman D, Morales-Kastresana A, et al., Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res 2013; 19: 1044-53.
24. Watts TH., TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005; 23: 23-68.
25. Zhou P, L'Italien L, Hodges D, et al., Pivotal roles of CD4+ effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors. J Immunol 2007; 179: 7365-75.
26. Ramirez-Montagut T, Chow A, Hirschhorn-Cymerman D, et al., Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J Immunol 2006; 176: 6434-42.
27. Bulliard Y, Jolicoeur R, Windman M, et al., Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 2013; 210: 1685-93.
28. Nocentini G, Ronchetti S, Petrillo MG, et al., Pharmacological modulation of GITRL/GITR system: therapeutic perspectives. Br J Pharmacol 2012; 165: 2089-99.
29. Murphy GP, Hrushesky WJ., A murine renal cell carcinoma. J Natl Cancer Inst 1973; 50: 1013-25.
30. Briles EB, Kornfeld S., Isolation and metastatic properties of detachment variants of B16 melanoma cells. J Natl Cancer Inst 1978; 60: 1217-22.
31. Wang M, Bronte V, Chen PW, et al., Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol 1995; 154: 4685-92.
32. Jiang Q, Weiss JM, Back T, et al., mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment. Cancer Res 2011; 71: 4074-84.
33. Xin H, Zhang C, Herrmann A, et al., Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 2009; 69: 2506-13.
34. Murphy JT, Burey AP, Beebe AM, et al., Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice. Blood 2014; 123: 2172-80.
35. Ko JS, Rayman P, Ireland J, et al., Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 2010; 70: 3526-36.
36. Growney JD, Clark JJ, Adelsperger J, et al., Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 2005; 106: 721-4.
37. Coe D, Begom S, Addey C, et al., Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy. Cancer Immunol Immun 2010; 59: 1367-77.
38. Huang B, Lei Z, Zhao J, et al., CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett 2007; 252: 86-92.
39. Yang L, Huang JH, Ren XB, et al., Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008; 13: 23-35.
40. Curiel TJ, Coukos G, Zou LH, et al., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-9.
41. Mantovani A, Sica A., Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010; 22: 231-7.
42. Bae E, Kim WJ, Kang YM, et al., Glucocorticoid-induced tumour necrosis factor receptor-related protein-mediated macrophage stimulation may induce cellular adhesion and cytokine expression in rheumatoid arthritis. Clin Exp Immunol 2007; 148: 410-18.
43. Kim WJ, Bae EM, Kang YJ, et al., Glucocorticoid-induced tumour necrosis factor receptor family related protein (GITR) mediates inflammatory activation of macrophages that can destabilize atherosclerotic plaques. Immunology 2006; 119: 421-9.
44. Weiss JM, Ridnour LA, Back T, et al., Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy. J Exp Med 2010; 207: 2455-67.
45. Santoni M, Berardi R, Amantini C, et al., Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor. Int J Cancer J Int Du Cancer 2014; 134: 2772-7.
46. Edwards JP, Emens LA., The multikinase inhibitor sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE(2) in murine macrophages. Int Immunopharmacol 2010; 10: 1220-8.
47. Hipp MM, Hilf N, Walter S, et al., Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 2008; 111: 5610-20.
48. Sica A, Bronte V., Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007; 117: 1155-66.
49. Liu J, Blake SJ, Smyth MJ, et al., Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies. Clin Transl Immunol 2014; 3: e22.
50. Havas HF, Berney S, Goodis A, et al., Effect of splenectomy on the immune response of BALB/c mice bearing an immunoglobulin M plasmacytoma (TEPC-183). Cancer Res 1979; 39: 3783-7.